Related Experiment Video
Updated: Jan 30, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent
Enrico Frigoli1, Pieter Smits2, Pascal Vranckx3
1Clinical Trials Unit, University of Bern, Bern, Switzerland.
Insights
Shorter antiplatelet therapy is effective for high-bleeding risk patients after stent implantation. The MASTER DAPT trial found abbreviated dual-antiplatelet therapy (DAPT) non-inferior to standard DAPT for safety and efficacy.
Area of Science:
- Cardiology
- Interventional Cardiology
- Clinical Trials
Background:
- Optimal antiplatelet therapy duration is unknown for high-bleeding risk (HBR) patients with coronary artery disease treated with newer-generation drug-eluting bioresorbable polymer-coated stents.
- MASTER DAPT addresses this gap by comparing abbreviated vs. standard antiplatelet therapy durations.
Purpose of the Study:
- To determine the optimal duration of antiplatelet therapy in HBR patients undergoing sirolimus-eluting bioresorbable polymer-coated stent implantation.
- To assess the noninferiority and superiority of abbreviated antiplatelet therapy compared to standard duration.
Main Methods:
- The MASTER DAPT trial is a randomized controlled trial involving approximately 4,300 HBR patients across over 100 centers globally.
- Patients received a mandatory 30-day dual-antiplatelet therapy (DAPT) followed by randomization to either abbreviated (1-month DAPT) or standard DAPT regimens.
- Primary endpoints include net adverse clinical and major adverse cardiac/cerebral events, and secondary endpoints focus on bleeding events.
Main Results:
- The study is powered to assess noninferiority of abbreviated antiplatelet therapy regarding net adverse clinical and major adverse cardiac and cerebral events.
- It will also assess superiority in terms of major or clinically relevant nonmajor bleeding events.
Conclusions:
- The MASTER DAPT study is the first randomized controlled trial to investigate optimal antiplatelet therapy duration in HBR patients treated with sirolimus-eluting bioresorbable polymer-coated stents.
- Findings will guide clinical practice for managing HBR patients undergoing stenting.
Background:
The optimal duration of antiplatelet therapy in high-bleeding risk (HBR) patients with coronary artery disease treated with newer-generation drug-eluting bioresorbable polymer-coated stents remains unclear.
Design:
MASTER DAPT (clinicaltrial.govNCT03023020) is an investigator-initiated, open-label, multicenter, randomized controlled trial comparing an abbreviated versus a standard duration of antiplatelet therapy after bioresorbable polymer-coated Ultimaster (TANSEI) sirolimus-eluting stent implantation in approximately 4,300 HBR patients recruited from ≥100 interventional cardiology centers globally. After a mandatory 30-day dual-antiplatelet therapy (DAPT) run-in phase, patients are randomized to (a) a single antiplatelet regimen until study completion or up to 5 months in patients with clinically indicated oral anticoagulation (experimental 1-month DAPT group) or (b) continue DAPT for at least 5 months in patients without or 2 in patients with concomitant indication to oral anticoagulation, followed by a single antiplatelet regimen (standard antiplatelet regimen). With a final sample size of 4,300 patients, this study is powered to assess the noninferiority of the abbreviated antiplatelet regimen with respect to the net adverse clinical and major adverse cardiac and cerebral events composite end points and if satisfied for the superiority of abbreviated as compared to standard antiplatelet therapy duration in terms of major or clinically relevant nonmajor bleeding. Study end points will be adjudicated by a blinded Clinical Events Committee.
Conclusions:
The MASTER DAPT study is the first randomized controlled trial aiming at ascertaining the optimal duration of antiplatelet therapy in HBR patients treated with sirolimus-eluting bioresorbable polymer-coated stent implantation.
Related Concept Videos
Dosage Regimens: Designs and Approaches
Bioavailability Study Design: Healthy Subjects Versus Patients
Dosage Regimen Designs: Nomograms and Tabulations
Design Example: Managing Concrete Workability
Master Transcription Regulators
Polymers

